Antonella P.
- Country
- Italy
- Department
- Oncologia Medica (study is conducted at Largo Agostino Gemelli 8, Roma 00168)
Research Overview
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Phase 3 Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
- Phase 2 Randomized Study of PF-07220060 and Letrozole Versus Letrozole in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
Data & Insights
Has run more than one trial at 105 of 332 partner sites.
Specializations
Advanced Breast Cancer Treatment
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on developing innovative therapeutic approaches for advanced and metastatic cases.
- Triple Negative Breast Cancer (TNBC)
- Metastatic Breast Cancer Management
- Hormone Receptor-Positive Disease
Their research encompasses both localized and systemic treatment strategies for breast cancer patients.
Immunotherapy Applications
The investigator conducts research in immunotherapeutic approaches for breast cancer treatment, including studies with T-cell activation strategies and novel combination therapies.
- Immune Checkpoint Inhibition
- Combination Immunotherapy
- Treatment-Resistant Disease
Their work includes evaluation of immune response in various breast cancer subtypes.
Endocrine Therapy Innovation
Expertise in endocrine therapy resistance and development of novel therapeutic strategies for hormone-dependent breast cancers, including neoadjuvant approaches.
- ESR1 Mutation Studies
- Targeted Therapy Combinations
- Biomarker Assessment
The research focuses on overcoming treatment resistance in hormone-positive breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.